RankAlpha logo
Back to Rankings

OCUL

Ocular TherapeutixC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
Successful label expansion or a material partnering/financing win extends runway, validates recurring revenue and margins, and pushes valuation toward the bull target (~+60% from the anchor).
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +11.7.
What can break
Regulatory setbacks, weak commercial adoption, or a dilutive financing round materially reduce per-share value, pushing the stock toward the bear target (>‑40% from the anchor).
Momentum
37
Value
41
Sentiment
83
Setup hits (3d)
— · Net —
AI TargetsBase $12.61 · Bull $18.34 · Bear $6.88
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-05 • Model: RankAlpha Sentiment AI
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net —
Target $27.17
Why
Momentum37 · Δ7d -14.0
Value41 · Δ7d -0.1
Sentiment83 · Δ7d +11.7
So what
Balanced signals. Wait for confirmation before sizing up.
Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits
Lead driver: Sentiment · See AI snapshot
Momentum
37
26% active weight
Current posture
7d trendSoftening
Δ7d
-14.0
Δ21d
-23.7
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
83
34% active weight
Current posture
7d trendImproving
Δ7d
+11.7
Δ21d
+9.8
Why this grade

Composite grade C. Momentum 36.7 / Value 41.1 / Sentiment 82.6

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.96B
Beta
0.91
Shares Out
218.96M
P/E (TTM) · Derived
-6.3
P/S (TTM)
44.11
P/FCF (TTM) · Derived
-7.43
Rev YoY
+0.8%
EPS YoY
+4.6%
Gross Margin
+87.2%
Op Margin
-449.7%
Net Debt
-$660.09M
Current Ratio
14.81
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology